BioSpace News Archive

The global Cancer Immunotherapy Market is expected to reach USD 153.03 Billion by 2027, according to a new report by Emergen Research.

The Global Minimally Invasive Biopsy Technologies Market is projected to reach USD 3.98 billion in 2027.

According to a recent report by Emergen Research, the market for non-invasive prenatal testing would reach USD 8.75 billion by 2027.

Trethera Corporation announces that the United States Patent and Trademark Office issued a Notice of Allowance for a composition of matter patent covering the polymorphic form of TRE-515.

Boston Heart Diagnostics, part of the Eurofins network of companies, announces the launch of LipidSeq™, a revolutionary genetic test for cardiovascular disease.

Following the FDA approval of ZYNTEGLO® (betibeglogene autotemcel), also known as beti-cel, for the treatment of beta-thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions, today bluebird bio released details of its U.S. commercial infrastructure to support rapid access to ZYNTEGLO.

Latest Study on “Bioanalytical Testing Services Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2022-2030”.

Latest Study on “Biotechnology Instruments Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2022-2030”.

Annexon, Inc., a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, announced that it has granted equity inducement awards to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan.

Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”) today announced it will report its second quarter 2022 financial and operating results after the close of U.S. financial markets on Wednesday, August 24, 2022.